Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Matvey Brokhin"'
Publikováno v:
Frontiers in Endocrinology, Vol 10 (2019)
Background: Recent studies identify a significant number of treated hypothyroid patients who express dissatisfaction with their therapy. At present there are sufficient measures of thyroid function to enable the clinician to establish a diagnosis of
Externí odkaz:
https://doaj.org/article/fdfe9b55e7fc4a498151638273751c09
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 10 (2019)
Frontiers in Endocrinology, Vol 10 (2019)
Background: Recent studies identify a significant number of treated hypothyroid patients who express dissatisfaction with their therapy. At present there are sufficient measures of thyroid function to enable the clinician to establish a diagnosis of
Publikováno v:
Clinical Endocrinology. 76:582-585
Summary Context Thyroid cancer survivors represent a unique population in which the potential long-term effects of brief periods of intentional thyroid hormone withdrawal and/or prolonged periods of iatrogenic hyperthyroidism on body weight and body
Publikováno v:
Thyroid : official journal of the American Thyroid Association. 22(8)
Current management guidelines suggest that 6-12 months after total thyroidectomy and radioactive iodine remnant ablation (RAI-RA), patients with differentiated thyroid cancer should be re-evaluated with serum thyroglobulin (Tg) and neck ultrasonograp
Publikováno v:
Clinical endocrinology. 76(4)
Thyroid cancer survivors represent a unique population in which the potential long-term effects of brief periods of intentional thyroid hormone withdrawal and/or prolonged periods of iatrogenic hyperthyroidism on body weight and body mass were evalua
Autor:
Jatin P. Shah, Gal Omry, Ashok R. Shaha, James A. Fagin, Rebecca Leboeuf, R. Michael Tuttle, Mithat Gonen, Hernán Tala, Matvey Brokhin, Ronald Ghossein
A risk-adapted approach to management of thyroid cancer requires risk estimates that change over time based on response to therapy and the course of the disease. The objective of this study was to validate the American Thyroid Association (ATA) risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16fb05600febaa4d2ff171fe01756255
https://europepmc.org/articles/PMC4845674/
https://europepmc.org/articles/PMC4845674/
Autor:
Gal Omry, Matvey Brokhin, Norma Lopez, Steve Larson, Rebecca Leboeuf, Ravinder K. Grewal, Shaye M. Minkowitz, R. Michael Tuttle
Publikováno v:
Thyroid : official journal of the American Thyroid Association. 20(3)
In December 2007, the USFDA approved recombinant human thyroid stimulating hormone (rhTSH) for radioiodine remnant ablation after total thyroidectomy in patients with well-differentiated thyroid cancer without evidence of metastatic disease. Because
Autor:
R. Michael Tuttle, Andrew J. Martorella, Matvey Brokhin, Richard J. Robbins, Steven M. Larson, Gal Omry, Ravinder K. Grewal, Martin Fleisher
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 49(5)
Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (rhTSH) stimulation effectively ablates the normal thyroid remnant. However, no published study has determined the effectiveness of rhTSH preparations on the im
Autor:
Matvey Brokhin, Irwin Klein
Publikováno v:
Clinical Cornerstone. 7:S28-S29
Publikováno v:
Thyroid. :120424074259007